SciSparc Ltd. ( (SPRC) ) has issued an update.
On February 4, 2025, SciSparc Ltd. announced that its collaboration with Clearmind Medicine Inc. has resulted in the publication of a patent application in Mexico for a treatment targeting binge behavior. This innovative therapy combines MDMA with N-Acylethanolamines, aiming to address behaviors such as alcohol consumption, eating, and tobacco use. The collaboration signifies ongoing research into psychedelic molecule-based treatments, with 13 patents filed across various jurisdictions, potentially strengthening SciSparc’s position in the pharmaceutical industry.
More about SciSparc Ltd.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company that focuses on developing therapies for central nervous system disorders and rare diseases. The company is involved in drug development programs utilizing cannabinoid pharmaceuticals, with efforts in treating conditions like Tourette Syndrome, Alzheimer’s disease, autism, and status epilepticus. SciSparc also has a subsidiary that sells hemp seed oil products on Amazon.
YTD Price Performance: 12.76%
Average Trading Volume: 8,585,975
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.58M
See more insights into SPRC stock on TipRanks’ Stock Analysis page.